Sanofi has agreed to acquire Blueprint Medicines for $9.5 billion, focusing on the innovative drug Ayvakit and expanding its immunology pipeline.

Target Company Overview

On June 2, 2025, French pharmaceutical giant Sanofi announced its agreement to acquire Boston-based biotechnology company Blueprint Medicines for approximately $9.5 billion. The focus of this acquisition is Blueprint's leading therapeutic, Ayvakit (avapritinib), which stands out as the sole approved treatment for advanced systemic mastocytosis in both the European Union and the United States. In the first quarter of 2025 alone, Ayvakit generated an impressive $150 million in sales, with analysts projecting potential peak annual sales of around $2 billion. Systemic mastocytosis is an immunological disorder characterized by the over-activation of mast cells, leading to an accumulation of these cells in various organs and resulting in severe allergy-like symptoms; in extreme cases, it can lead to organ damage.

In addition to Ayvakit, Sanofi will also gain access to Blueprint's robust immunology pipeline, which includes several promising compounds in various stages of development. Notably, this pipeline includes a Phase III asset that may address additional types of mastocytosis, further expanding Sanofi's therapeutic offerings.

Industry Overview

The biotechnology industry in the United States represents a dynamic and innovative sector, characterized by ongoing breakthroughs in medical treatments and therapies. It has been instrumental in the development of numerous targeted therapies and biologics, driving advancements i